Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)

Core Insights - Gilead Sciences is preparing for the commercialization of its BCMA CAR T therapy, anito-cel, in partnership with Arcellx, with a launch anticipated next year [5]. Efficacy and Safety Data - The BCMA CAR T therapy has demonstrated a compelling 62% complete response rate and a 97% overall response rate, indicating strong efficacy in both high-risk and general populations with myeloma [6]. - Safety data shows that 86% of patients experienced grade one or no cytokine release syndrome (CRS) events, with the majority only experiencing mild symptoms such as fever [6]. - Long-term neurotoxicities associated with the therapy are also showing differentiation, suggesting a favorable safety profile [6].